Paris, France and Cambridge, UK 1/18/16—Publicly held Novacyt, a provider of cancer and infectious disease diagnostics, has agreed to acquire Primer Design for £9.85 million ($14.1 million = £0.70 = $1) in cash and stock in addition to £2.5 million ($3.6 million) based on sales targets. UK-based Primer Design offers real-time PCR kits, reagents and instruments. Primer’s revenues grew at a three-year compound annual rate of 32% to £5.3 million ($7.6 million). Novacyt stated that the acquisition expands its technology platforms and enables Primer Design to further penetrate diagnostics end-markets. “Upon completion, Primer Design’s extensive research-only product portfolio will be developed into high-value, clinically approved diagnostics to be sold through the Novacyt sales channel,” stated Novacyt CEO Graham Mullis. The transaction is subject to Novacyt shareholder approval.